Infectious Arthritis
Also known as: Septic arthritis
Methodology & AI Transparency ⓘ
Infectious Arthritis Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Most kinds of arthritis cause pain and swelling in your joints.
- 2 Real-world patient consensus: Mapped to Osteoarthritis, Gout & Joint Pain under ICD-10-CM M19.6 for Infectious Arthritis clinical workups.
- 3 Typical cash cost range: Clinicians assessing Infectious Arthritis focus on articular hyaline cartilage in Infectious Arthritis (M19.6: proteoglycan degradation) and targeted history.
- 4 Top reported side effects / signs: Objective lab/clinical target for Infectious Arthritis: Serum Uric Acid in Infectious Arthritis (M19.6: (Gout Target)) (< 6.0 mg/dL (< 5.0 mg/dL with tophi) (M19.6)) and hs-CRP & Erythrocyte in Infectious Arthritis (M19.6: Sedimentation Rate).
Ask our AI Specialists anything about Infectious Arthritis
What Is Infectious Arthritis?
Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Infectious arthritis is an infection in the joint. The infection comes from a bacterial, viral, or fungal infection that spreads from another part of the body. Symptoms of infectious arthritis include: Intense pain in the joint Joint redness and swelling Chills and fever Inability to move the area with the infected joint One type of infectious arthritis is reactive arthritis. The reaction is to an infection somewhere else in your body. The joint is usually the knee, ankle, or toe.
Pathophysiology, Underlying Causes & Clinical Presentation
Pathophysiologically, Infectious Arthritis (ICD-10 M19.6) is driven by articular hyaline cartilage in Infectious Arthritis (M19.6: proteoglycan degradation); Cross-referenced with NIH MeSH (Arthritis, Infectious), specialists in Osteoarthritis, Gout & Joint Pain monitor hs-CRP & Erythrocyte in Infectious Arthritis (M19.6: Sedimentation Rate) to gauge tissue recovery.
Common Symptoms & Clinical Signs
- • Intense pain in the joint
- • Joint redness and swelling
- • Presentation of Infectious Arthritis (M19.6): sudden, intensely painful, in Infectious Arthritis (M19.6: red swollen big-toe)
- • Secondary Infectious Arthritis clinical sign: localized tendon or in Infectious Arthritis (M19.6: bursa tenderness limiting)
Primary Federal Reference: NIH / National Library of Medicine MedlinePlus Entry ↗
Infectious Arthritis Diagnostic Classification & Lab Markers
| Metric | Verified Benchmark | Source |
|---|---|---|
| ICD-10-CM Diagnostic Code | M19.6 | WHO / CMS ICD-10-CM Clinical Classification |
| Clinical Specialty Hub | Osteoarthritis, Gout & Joint Pain | NIH MedlinePlus Health Topics |
| Diagnostic / Lab Marker: Serum Uric Acid in Infectious Arthritis (M19.6: (Gout Target)) | < 6.0 mg/dL (< 5.0 mg/dL with tophi) (M19.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: hs-CRP & Erythrocyte in Infectious Arthritis (M19.6: Sedimentation Rate) | hs-CRP < 1.5 mg/L; ESR < 15 mm/hr (M19.6) | Clinical Reference Target Range |
| Diagnostic / Lab Marker: Weight-Bearing Joint Radiograph [Infectious Arthritis M19.6] | Preserved joint-space width (M19.6) | Clinical Reference Target Range |
FDA-Monographed Medications & Public Cash Price Reference for Infectious Arthritis
| Medication | Pharmacologic Class | Patient Worth-It | CMS NADAC / Unit | Typical Lowest Cash |
|---|---|---|---|---|
| Universal Arthritis and Sport (Methyl Salicylate, Capsicum) Universal Arthritis and Sport • RxCUI 2671957-B52000302 | Non-Standardized Plant Allergenic Extract | 91% | $1.2600 | $ 99.22 /mo |
| Lidocaine 4.5%, Diclofenac 1% Diclona • RxCUI 2600049 | Amide Local Anesthetic | 82% | $0.0989 | $ 12.50 /mo |
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Infectious Arthritis)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Managing Psoriatic arthritis: Can Upadacitinib on enthesitis Make a Real Difference? (What a 639-Person Study Found) UPA15 is associated with a comprehensive improvement in enthesitis, with improvements observed after 12 weeks of treatment. Rheumatology (Oxford, England) • 2024-11-01 • Phase III Randomized Trial | N = 639 | 93/100 | PMID 38331400 ↗ |
| New Insights on Effectiveness of Intrarectal Povidone-iodine Cleansing Plus Formalin Disinfection: What a 633-Participant Study Found Intrarectal povidone-iodine cleansing plus formalin disinfection of the biopsy needle tip was associated with a reduction in infectious complications after transrectal prostate biopsy. The Journal of urology • 2022-12-15 • Phase III Randomized Trial | N = 633 | 87/100 | PMID 36006040 ↗ |
| New Insights on Prognostic Impact of Post-operative Infectious Complications in Gastric Cancer: What a 224-Participant Study Found This study could not indicate the negative prognostic influence of ICs in gastric cancer patients receiving NAC, which might be canceled by NAC. Journal of gastrointestinal cancer • 2024-09-15 • Phase III Randomized Trial | N = 224 | 82/100 | PMID 38703333 ↗ |
| Can This Approach Help? Inside the Latest Research on Extension study of the safety and real-world benefits of CLS-TA for treatment of Approximately 50% of patients did not require additional treatment for up to 9 months following the last CLS-TA administration. The British journal of ophthalmology • 2022-08-15 • Phase III Randomized Trial | N = 33 | 82/100 | PMID 33712478 ↗ |
| Can This Approach Help? Inside the Latest Research on Early clinical response associates with long-term outcomes with ixekizumab in This analysis reinforces the current recommendation that continuing treatment in those achieving ASDAS CII at week 12 and/or week 24 increases the likelihood of obtaining ID/LDA at week 52. RMD open • 2024-07-14 • Phase III Randomized Trial | N = 33 | 82/100 | PMID 39004432 ↗ |
Infectious Arthritis Patient Community & “People Like Me” Threads
Filter Infectious Arthritis community threads and patient logs by age, biological sex, dosage, and treatment duration.